Skip to main content
BayerIn development

Bayer Wins FDA Fast-Track for Lynkuet as JPMorgan Flags Stretched Q3 Hopes

Source: Autobound Signal API · 72 signals tracked for Bayer · updated

Get Bayer's live signals in Claude or ChatGPT, or by API

AskWhat changed at Bayer this week? Use Autobound signals for bayer.com.

What happened

Bayer's supplemental application for its drug Lynkuet (elinzanetant) has been accepted for Priority Review by the U.S. FDA for treating moderate-to-severe vasomotor symptoms in women undergoing endocrine therapy for hormone receptor-positive breast cancer.

Source

Article excerpt

Highlighted: the sentence this signal was extracted from

US regulators have agreed to expedite their review of one of Bayer's most closely watched pipeline candidates. The FDA accepted a supplemental application for Lynkuet, whose active ingredient is elinzanetant, and handed the filing Priority Review status - a designation that typically shortens the approval timeline well below the standard track. The submission covers the drug's use in treating moderate-to-severe vasomotor symptoms in women undergoing endocrine therapy for hormone receptor-positive breast cancer. For the Leverkusen-based group, the regulatory nod marks a milestone in widening Lynkuet's therapeutic reach, targeting patients who endure severe hot flushes and similar complaints as a consequence of their cancer treatment. While pushing its internal development programs forward, Bayer is simultaneously shedding older products. Fellow German pharma company Grünenthal has struck a deal to acquire the rights to the cancer drug Stivarga, in a transaction worth up to EUR 375 million. Completion hinges on customary conditions and antitrust clearances, with both sides expecting the deal to close around the end of 2026 or early 2027. The divestment slots into a broader reshaping of Bayer's pharmaceutical operations. On the manufacturing side, the company is planning long-term capacity expansions, including a production site in the US state of Ohio carrying an estimated...

Keep reading with a free account

The rest of this article, and every signal for Bayer, is in your free account.

Extracted by Autobound

From the Signal API record
Event
In development

What this signalsWork in development often leads to new buying for tools, data and services.

Product
Lynkuet
Recognition
Priority Review status

Companies

  • Food and Drug AdministrationRelated companyfda.gov

The full record

From the Signal API record

Topics and mentions

Product tags

  • general technology
  • medical

Extraction

Confidence
90%
Detected
Oct 4, 2026
signal_type
news
signal_subtype
is_developing

Use this data

Get every in development signal for Bayer and the companies you sell to, in the tools you already use.

  1. Ask Claude about it

    Connect Autobound to Claude, Claude Code or Cursor with MCP. Then ask: “What changed at Bayer this week?”

  2. Send it to your own tools

    The Signal API returns in development signals for any list of companies as JSON, for your CRM, warehouse or app.

  3. Try it free

    Sign up and spend your free credits on the companies you sell to.

    Start Free1,000 free credits

The API returns more than this page shows

This page shows a preview. The full news record in the Signal API and MCP can also have these 8 fields. Some fields are empty for some signals.

Company

  • linkedin_urlValue in the API
  • industriesValue in the API
  • employee_count_lowValue in the API
  • employee_count_highValue in the API
  • revenueValue in the API
  • descriptionValue in the API

Signal

  • signal_nameValue in the API
  • associationValue in the API
Show the full JSONThe record on this page and the API request

GET /v1/signals/c83f6714-149a-cc5e-4405-48ef5b9dc685 returns this record as JSON. POST /v1/companies/enrich returns every signal for bayer.com.

{
  "signal_id": "c83f6714-149a-cc5e-4405-48ef5b9dc685",
  "signal_type": "news",
  "signal_subtype": "is_developing",
  "detected_at": "2026-10-04T17:01:18+00:00",
  "company": {
    "name": "Bayer",
    "domain": "bayer.com"
  },
  "data": {
    "url": "https://www.ad-hoc-news.de/boerse/news/unternehmensnachrichten/bayer-wins-fda-fast-track-for-lynkuet-as-jpmorgan-flags-stretched-q3-hopes/70227341",
    "title": "Bayer Wins FDA Fast-Track for Lynkuet as JPMorgan Flags Stretched Q3 Hopes - AD HOC NEWS",
    "excerpt": "US regulators have agreed to expedite their review of one of Bayer's most closely watched pipeline candidates. The FDA accepted a supplemental application for Lynkuet, whose active ingredient is elinzanetant, and handed the filing Priority Review status - a designation that typically shortens the approval timeline well below the standard track. The submission covers the drug's use in treating moderate-to-severe vasomotor symptoms in women undergoing endocrine therapy for hormone receptor-positive breast cancer. For the Leverkusen-based group, the regulatory nod marks a milestone in widening Lynkuet's therapeutic reach, targeting patients who endure severe hot flushes and similar complaints as a consequence of their cancer treatment. While pushing its internal development programs forward, Bayer is simultaneously shedding older products. Fellow German pharma company Grünenthal has struck a deal to acquire the rights to the cancer drug Stivarga, in a transaction worth up to EUR 375 million. Completion hinges on customary conditions and antitrust clearances, with both sides expecting the deal to close around the end of 2026 or early 2027. The divestment slots into a broader reshaping of Bayer's pharmaceutical operations. On the manufacturing side, the company is planning long-term capacity expansions, including a production site in the US state of Ohio carrying an estimated price...",
    "product": "Lynkuet",
    "summary": "Bayer's supplemental application for its drug Lynkuet (elinzanetant) has been accepted for Priority Review by the U.S. FDA for treating moderate-to-severe vasomotor symptoms in women undergoing endocrine therapy for hormone receptor-positive breast cancer.",
    "planning": true,
    "image_url": "https://mdb.ad-hoc-news.de/bild/bild-2704605_1920_1080.webp",
    "confidence": 0.9,
    "recognition": "Priority Review status",
    "product_data": {
      "name": "Lynkuet",
      "full_text": "Lynkuet, whose active ingredient is elinzanetant",
      "fuzzy_match": false
    },
    "product_tags": [
      "general_technology",
      "medical"
    ],
    "published_at": "2026-10-04T17:01:18Z",
    "article_sentence": "The FDA accepted a supplemental application for Lynkuet, whose active ingredient is elinzanetant, and handed the filing Priority Review status - a designation that typically shortens the approval timeline well below the standard track.",
    "related_company_name": "Food and Drug Administration",
    "related_company_domain": "fda.gov"
  }
}

Long text fields are shortened on this page.

Looking up one signal by its id is free. Enrich costs 2 credits per signal returned; a call with no results is free.